Effect of Pollen-Specific Subcutaneous Immunotherapy (SCIT) on
Tree nut allergy (Table 2)
Van Hoffen et al.15 contacted a DBPC study in adults
with birch pollen and hazelnut allergy. After a year on birch-
pollen-SCIT, no changes in eliciting dose (ED) and symptom score during
the exit double-blinded placebo-controlled food challenge (DBPCFC) were
noted.
Alonso et al.26 investigated the effect of 1 year of
plane-pollen-SCIT in 16 adults, including six with walnut allergy and
six with hazelnut allergy. Three walnut-allergic patients completed the
study, of which one increased the ED, and two reached the highest dose
of 25g at the exit oral food challenge (OFC). Five hazelnut allergic
patients underwent exit OFC; in one the ED decreased from 20 to 0,1gr,
in one remained unchanged, and the rest reached the highest dose.